Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Next Previous
X
Search
Trial Profile

A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Bicalutamide; Leuprorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Biomarker

    • Most Recent Events

    • 30 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
    • 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 24 Jul 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top